An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 [interleukin-4-(38-37)-PE38KDEL] in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors

Trial Profile

An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 [interleukin-4-(38-37)-PE38KDEL] in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2013

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Renal cancer
  • Focus Adverse reactions
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 19 Sep 2005 New trial record.
    • 03 Jun 2003 Interim results reported at ASCO 2003.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top